Ceralasertib
CAS 1352226-88-0
(R)-imino(methyl)(1-{6-[(3R)-3-methylmorpholin-4-yl]-2-{1H-pyrrolo[2,3-c]pyridin-4-yl}pyrimidin-4-yl}cyclopropyl)-lambda6-sulfanone
imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-λ6-sulfane
UNII 85RE35306Z
| Molecular Weight | 412.51 |
|---|---|
| Formula | C20H24N6O2S |
AZD 6738, ATR KINASE INHIBITOR AZD6738, AZD-6738, AZD6738, WHO 10842
Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC50 of 1 nM.
Ceralasertib is an investigational new drug that is being evaluated for the treatment of cancer.[1] It is an ATR kinase inhibitor.[2]
- Originator AstraZeneca; University of Pennsylvania
- Developer Acerta Pharma; AstraZeneca; Dana-Farber Cancer Institute; Gustave Roussy; National Cancer Institute (France); Samsung Medical Center; University of California at San Francisco; University of Pennsylvania
- Class Antineoplastics; Cyclopropanes; Imines; Ketones; Morpholines; Organic sulfur compounds; Pyridines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action ATR protein inhibitors
- Phase III Non-small cell lung cancer
- Phase IICholangiocarcinoma; Gynaecological cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Phase I/IIChronic lymphocytic leukaemia
- Phase IChronic myelomonocytic leukaemia; Myelodysplastic syndromes
- PreclinicalDiffuse large B cell lymphoma; Type 1 diabetes mellitus
- DiscontinuedHaematological malignancies; Non-Hodgkin’s lymphoma; Squamous cell cancer
- 22 Apr 2025AstraZeneca plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) (PO) in April 2025(NCT06929260)
- 23 Dec 2024AstraZeneca plans a phase I trial for Non-small Cell Lung Cancer, Ovarian Cancer, or Endometrial Cancer in United Kingdom(PO) In January 2025 (NCT06754761)
- 07 Dec 2024Updated efficacy and adverse event data from a phase I trial in Myelodysplastic syndrome presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
SCHEME
PATENT
WO2011154737
CN112939966
PAPER
https://pubs.acs.org/doi/abs/10.1021/acs.oprd.0c00482
4-{4-[(3R)-3-methyl-4-morpholinyl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]-2-
pyrimidinyl}-1H-pyrrolo[2,3-b]pyridine (1).
Recent Applications of Pd-Catalyzed Suzuki–Miyaura and Buchwald–Hartwig Couplings in Pharmaceutical Process Chemistry
- January 2022
- Organics 3(1):1-21
References
- ^ “Ceralasertib – AstraZeneca/University of Pennsylvania”. AdisInsight. Springer Nature Switzerland AG.
- ^ Mavroeidi D, Georganta A, Panagiotou E, Syrigos K, Souliotis VL (February 2024). “Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes”. International Journal of Molecular Sciences. 25 (5): 2767. doi:10.3390/ijms25052767. PMC 10932434. PMID 38474014.
- [1]. Vendetti FP, et al. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of CDDP to resolve ATM-deficient non-small cell lung cancer in vivo. [Content Brief][2]. Kim HJ, et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int J Cancer. 2017 Jan 1;140(1):109-119. [Content Brief]
| Clinical data | |
|---|---|
| Other names | AZD-6738 |
| Legal status | |
| Legal status | Investigational |
| Identifiers | |
| showIUPAC name | |
| CAS Number | 1352226-88-0 |
| PubChem CID | 54761306 |
| IUPHAR/BPS | 9390 |
| DrugBank | DB14917 |
| ChemSpider | 58828171 |
| UNII | 85RE35306Z |
| KEGG | D11787 |
| ChEMBL | ChEMBL4285417 |
| PDB ligand | VJM (PDBe, RCSB PDB) |
| ECHA InfoCard | 100.232.607 |
| Chemical and physical data | |
| Formula | C20H24N6O2S |
| Molar mass | 412.51 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| showSMILES | |
| showInChI | |
////Ceralasertib, AZD 6738, Phase 3, Non-small cell lung cancer, ATR KINASE INHIBITOR AZD6738, AZD-6738, AZD6738, WHO 10842,
85RE35306Z